0001104659-22-123365.txt : 20221130 0001104659-22-123365.hdr.sgml : 20221130 20221130203301 ACCESSION NUMBER: 0001104659-22-123365 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221128 FILED AS OF DATE: 20221130 DATE AS OF CHANGE: 20221130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kelly Scott A. CENTRAL INDEX KEY: 0001703394 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-49908 FILM NUMBER: 221436955 MAIL ADDRESS: STREET 1: C/O CYTODYN INC. STREET 2: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytoDyn Inc. CENTRAL INDEX KEY: 0001175680 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 753056237 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 BUSINESS ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 BUSINESS PHONE: 360-980-8524 MAIL ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 FORMER COMPANY: FORMER CONFORMED NAME: CYTODYN INC DATE OF NAME CHANGE: 20031114 FORMER COMPANY: FORMER CONFORMED NAME: REXRAY CORP DATE OF NAME CHANGE: 20020617 4 1 tm2231600-3_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-11-28 0 0001175680 CytoDyn Inc. CYDY 0001703394 Kelly Scott A. 1111 MAIN STREET, SUITE 660 VANCOUVER WA 98660 0 1 0 0 CMO Common Stock 2022-11-30 4 A 0 16927 0.00 A 2184037 D Common Stock 782408 I By Spouse Non-qualified stock option (right to buy) 0.35 2022-11-28 4 A 0 2315439 0 A 2032-11-28 Common Stock 2315439 2315439 D Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. 241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026. /s/ Antonio Migliarese, Attorney-In-Fact 2022-11-30